Bristol-Myers Squibb Canada Co. v. Pharmascience Inc., 2023 FC 1023 (Apixaban*)
Assess.s Morgan - 2023-07-26
Read full decision. Automatically generated summary:
This assessment of costs is related to the Court’s Judgment and Reasons (2021 FC 354) ... BMS has submitted claims for assessable services totalling $309,791.76 and for disbursements totalling $419,964.00. I followed the instructions and guidance provided by the Court’s Judgment and Reasons dated April 22, 2021, and I found most of BMS’ claims to be reasonable and justifiable expenses for the concurrent litigation of two complex and layered intellectual property proceedings
Decision relates to:
- T-97-19 - BRISTOL-MYERS SQUIBB CANADA CO. ET AL v. PHARMASCIENCE
- T-98-19 - BRISTOL-MYERS SQUIBB CANADA CO. ET AL v. PHARMASCIENCE INC.